Item 1.01. Entry into a Material Definitive Agreement.

Asset Purchase Agreement

On August 17, 2021, Aerpio Pharmaceuticals, Inc. (the "Company") entered into an Asset Purchase Agreement (the "Purchase Agreement") with EyePoint Pharmaceuticals, Inc. ("EyePoint") pursuant to which the Company agreed to sell all of the Company's right, title and interest in and to the patents and patent applications related to (a) the Phase 2 program for razuprotafib in glaucoma, (b) the Phase 2 program of razuprotafib in COVID-19, and (iii) Preclinical Tie2 activating antibodies in return for a one-time cash payment of $450,000. The closing of the Purchase Agreement is contingent upon and effective after the closing of the merger of the Company with Aadi Bioscience, Inc., as approved by the stockholders of the Company on August 17, 2021, and as previously described in the Company's Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission (the "SEC") on May 17, 2021.

The foregoing description of the Purchase Agreement is not complete and is qualified in its entirety by reference to the full text of the Purchase Agreement, which is attached as Exhibit 10.1 hereto and incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.




(d) Exhibits



Exhibit
  No.                                    Description

10.1          Asset Purchase Agreement dated August 17, 2021, by and between
            Aerpio Pharmaceuticals, Inc. and EyePoint Pharmaceuticals, Inc. (filed
            herewith).*

104         Cover Page Interactive Data File (embedded within the Inline XBRL
            document).

* Certain exhibits and schedules to the Purchase Agreement have been omitted

pursuant to Item 601(a)(5) of Regulation S-K. A copy of any omitted schedule

and/or exhibit will be furnished to the SEC upon request.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses